Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommenda
AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating
With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.<
AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo
AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in
AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi